Introduction {#S0001}
============

Cancer is one of the leading causes of death in the world and chemotherapy is frequently used treatment for the management of cancer. There are various chemotherapeutic agents approved for the treatment of cancer but they lack specificity and are generally less tolerable.[@CIT0001] Ovarian cancer is amongst the deadliest cancers in women and is one of the leading causes of death.[@CIT0002] Treatments include de-bulking surgery and platinum-based chemotherapy.[@CIT0003] Despite a successful initial response from platinum-based drugs, tumors develop resistance and lead to reduced response.[@CIT0004]

To avoid these drawbacks of chemotherapy, it is necessary to incorporate natural therapeutic moieties having the potential to reduce tumor growth.[@CIT0005] It is of prime importance to explore the natural products having tumor inhibitory properties without harming healthy cells.[@CIT0006] Some natural products are also known to increase chemosensitization of the tumor and enhance the effectiveness of chemotherapeutic agents without harming normal body cells.[@CIT0007]

Curcumin is a phenolic derivative of turmeric. Curcumin is used as a therapeutic agent in various diseases including cancer. Curcumin has antiproliferative effect on breast cancer cell lines by inhibiting the orthenine decarboxylase activity.[@CIT0008] Curcumin also has chemopreventive effect against breast cancer.[@CIT0009] Some in-vivo studies support the antimetastatic role of curcumin.[@CIT0010] Several studies also support the therapeutic role of curcumin in ovarian cancer.[@CIT0011],[@CIT0012] Curcumin increases the sensitivity of the standard chemotherapy regime in resistant cancer cells. The anti-proliferative effect of curcumin is enhanced in combination with chemotherapeutic agents.[@CIT0013] Curcumin inhibits the cell cycle at the G~2~/M phase and renders the cells more sensitive to radiation. Curcumin induces apoptosis in cancer cells by inhibiting the DNA topoisomerase II.[@CIT0014]

The conventional administration of cisplatin in ovarian cancer produces severe side effects on vital organs such as kidney and liver. In recent era, various efforts have been made to reduce the undesirable effects by encapsulating in micelles, polymeric nanoparticles or coating with the lipids.[@CIT0015] Some studies support the role of curcumin to increase the chemosensitization of ovarian cancer and enhance the effectiveness of cisplatin on the ovarian cell lines.[@CIT0016] Curcumin is also known to reduce nephrotoxicity[@CIT0017] and ototoxicity caused by cisplatin.[@CIT0018] Curcumin overcomes the resistance of cisplatin and increases the therapeutic efficacy of cisplatin.[@CIT0019]

The conventional drug delivery system results in a burst release of chemotherapeutic agents, which may further increase side effects. Nanotechnology enables the drug to be delivered at the targeted site in a controlled manner.[@CIT0020] Nanoparticle-based systems enable the delivery of therapeutic agents to the specific cancer cells resulting in increased therapeutic benefits.[@CIT0021]

Lipid-polymer hybrid nanoparticles (LPHNPs) combine the structural advantage of polymer and biomimetic properties of lipids and enable the controlled release of drugs with high encapsulation efficiency.[@CIT0022] Lipid-polymer hybrid drug delivery system can incorporate hydrophilic and lipophilic drugs at the same time.[@CIT0023] Although polymeric nanoparticles and liposomes have been effectively used for drug delivery, but they suffer some drawbacks such as the stability problem of liposomes and aggregation of polymeric nanoparticles. To overcome these drawbacks associated with polymeric and liposomal drug delivery system we developed a lipid-polymer hybrid system for enhanced therapeutic outcomes.[@CIT0024]

Chitosan is a suitable polymer for drug delivery due to its biodegradability and low cost.[@CIT0025] Chitosan is a biocompatible polymer obtained from chitin. It has anionic drug delivery properties because of its cationic charge and can form complexes with anionic drugs such as naproxen[@CIT0026] and enoxaparin.[@CIT0027] Chitosan is also a suitable polymer for controlled drug delivery.[@CIT0028] Here we use chitosan as a polymer and Lipoid S75 as a lipid to prepare lipid-polymer hybrid nanoparticles for dual delivery of cisplatin and curcumin to enhance chemosensitization of tumor cell lines and increase the therapeutic output of cisplatin.

Materials and Methods {#S0002}
=====================

Materials {#S0002-S2001}
---------

Curcumin, Chitosan (Low molecular weight: 50,000--190,000 Da), MCF-7 breast cell lines and A2780 ovarian cell lines were purchased from Sigma Aldrich (Chemie, Germany). LIPOID S75 was received from the LIPOID (Newark, NJ, USA). Cisplatin was received as a gift sample from Pharmedic Laboratories (Pvt) Ltd, Pakistan. Ethanol and acetic acid were of analytical grade and purchased from Fisher Scientific (MA, USA). Cell Titer Blue^®^ and Cell Titer Glo^®^ were purchased from Promega^®^ (Wisconsin, USA). Roswell Park Memorial Institute Medium (RPMI), fetal bovine serum (FBS), and antimycotic, antibacterial solutions were obtained from CellGro (VA, USA). HOECHST 3342 was purchased from Molecular Probes Inc. (Eugene, OR). Paraformaldehyde was from Electron Microscopy Sciences (Hatfield, PA, USA). Trypan blue solution was obtained from Hyclone (Logan, UT, USA). Fluorescent dyes Rhodamine-123 and Rhodamine-PE were purchased from Sigma Aldrich (MA. USA). Flow cytometry (Beckton Dickinson FACS Calibur TM, NJ, USA) was used and Plate reader (Biotek) was used for cell count.

Preparation of Cisplatin and Curcumin Loaded LPHNPs {#S0002-S2002}
---------------------------------------------------

LPHNPs were prepared by ionic gelation method as described by Sonvico et al[@CIT0029] Briefly, 2.5mg of chitosan was dissolved in 23 mL of acetic acid solution with an overnight stirring and cisplatin was dissolved in the same solution while 50mg of lipid was dissolved in 2 mL of ethanol and curcumin was then dissolved in the same ethanolic solution. The ethanolic solution was added dropwise into acetic acid solution with constant stirring at 1000rpm for 30 mins. The lipid-polymer hybrid nanoparticles (LPHNPs) were formulated by the interaction of positively charged chitosan and negatively charged lipids ([Figure 1](#F0001){ref-type="fig"}). The LPHNPs with varying ratios of lipid to chitosan were prepared and were then centrifuged at 10,000rpm for 30 mins for further characterization.Figure 1Schematic diagram of formation of curcumin and cisplatin co-loaded LPHNPs.

The fluorescent dyes (0.5 mole percent) along with lipids were also dissolved in ethanolic solution to prepare nanoparticles for cell uptake studies. For cisplatin loaded LPHNPs only cisplatin was dissolved in acetic acid solution and for curcumin loaded LPHNPs only curcumin was dissolved in an ethanolic solution of lipid.

Size and Zeta Potential {#S0002-S2003}
-----------------------

The prepared LPHNPs were analyzed for size and surface charge using Zeta Sizer (Malvern, UK). The dynamic light scattering technique was used for the determination of size. 50µL of nanoparticle solution was placed in a cuvette and size was determined. Phosphate buffer saline was used for dilution to measure the surface charge. Measurement was performed at room temperature at 90° scattering angle and three readings were taken for each sample.

Entrapment Efficiency and Drug Loading {#S0002-S2004}
--------------------------------------

The entrapment of cisplatin and curcumin inside the lipid polymer hybrid nanoparticles was determined by an indirect method.[@CIT0030] The LPHNPs were prepared and centrifuged at 10,000 rpm, supernatant was used to measure the amount of un-entrapped drugs in the nanoparticles. The amount of un-entrapped drugs was measured using a UV spectrophotometer at 210 nm for cisplatin[@CIT0031] and 420 nm for curcumin.[@CIT0032] The entrapment efficiency and drug loading of cisplatin and curcumin was determined by following formulas: $$\documentclass[12pt]{minimal}
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Transmission Electron Microscopy {#S0002-S2005}
--------------------------------

The morphology of prepared LPHNPs was analyzed by using the transmission electron microscope (Jeol, USA). The samples of cisplatin and curcumin co-loaded LPHNPs were applied directly on the grid and suitable images were taken at different resolutions.

In vitro Drug Release {#S0002-S2006}
---------------------

The drug release studies were performed at pH7.4 using the dialysis bag method. The dialysis membrane with MWCO 10--12 kDa was used. The prepared hybrid nanoparticles loaded with 5 mg of cisplatin in chitosan solution and 5 mg of curcumin in lipid solution were suspended inside the dialysis bag and immersed in the phosphate buffer saline at 37°C and 100rpm. The samples were withdrawn at predetermined time intervals and the contents of cisplatin and curcumin were analyzed using the UV spectrophotometer.

Cell Cytotoxicity {#S0002-S2007}
-----------------

Cell viability studies were performed on ovarian cell lines to evaluate the therapeutic efficacy of hybrid nanoparticles. A2780 cell lines were used. Cells (5000) were seeded in each well of a 96 well plate and incubated at 25°C in 5% CO~2~. After overnight incubation the cells were treated with curcumin loaded LPHNPs, cisplatin loaded LPHNPs and co-loaded (Cisplatin+ curcumin) LPHNPs to observe the increased therapeutic effect of curcumin. After 4 hrs of treatment, the formulations were removed and replaced with fresh media and cell viability was observed using Cell Titer Blue counted by the plate reader (BioTek) after 24 hrs and 48 hrs of treatment.[@CIT0033]

Cell Uptake {#S0002-S2008}
-----------

Cell uptake studies were performed to measure the uptake of LPHNPs. Cells (500,000) were seeded in each well of a 6 well plate. After 24 hrs of incubation, cells were treated with co-loaded (cisplatin+curcumin) LPHNPs having rhodamine-123 and cisplatin loaded LPHNPs with Rhodamine-123. After 4 hrs of treatment, the cells were collected using trypsin and washed with PBS and then re-suspended in PBS and uptake of hybrid nanoparticles was measured using flow cytometry.

Fluorescence Microscopy {#S0002-S2009}
-----------------------

Cells (200,000) were seeded in each well of a 12 well plate containing microscopic glass slide. After overnight incubation, the cells were treated with co-loaded LPHNPs to observe the qualitative uptake by the cells. The fluorescent dyes rhodamine-123 and rhodamine-PE were incorporated inside the co-loaded LPHNPs and fluorescence was observed. After 4 hrs of treatment, the cells were collected and fixed using 4% paraformaldehyde and then treated with HOECHST 33342 and washed with PBS and mounted on microscopic slides using a mounting buffer and observed using KEYENCE (BZX710) fluorescence microscope.

Preparation of 3D Spheroids {#S0002-S2010}
---------------------------

The spheroids were prepared using MCF-7 breast cell lines. A 96 well plate was first coated with agarose 15% and cells (7000) were seeded in each well of a 96 well plate and centrifuged to create the collective layers of cells and placed in incubator. The plates were observed under the microscope for the development of spheroids and fresh media was replaced on alternative days for the growth of spheroids until the formation of 3D spheroids.[@CIT0034]

Cytotoxicity Studies Toward 3D Spheroids {#S0002-S2011}
----------------------------------------

The prepared spheroids were used to evaluate the therapeutic efficacy of LPHNPs and to measure the effect of added curcumin to the cisplatin loaded LPHNPs. The spheroids were treated with cisplatin loaded LPHNPs, curcumin and cisplatin co-loaded LPHNPs and cisplatin solution. After 24 and 48 hrs of treatment, the spheroids were collected and treated with Cell Titer Glo (CTG) protocol as per manufacturer instructions and cytotoxicity was evaluated using a plate reader (BioTek).

Cell Uptake Studies Using 3D Spheroids {#S0002-S2012}
--------------------------------------

The uptake of hybrid nanoparticles by 3D spheroids was evaluated quantitatively using flow cytometry. The LPHNPs were loaded with fluorescent dye rhodamine-PE to measure the uptake. The spheroids were treated with curcumin and cisplatin co-loaded LPHNPs and cisplatin loaded LPHNPs and after 4 hrs of treatment the cells were collected centrifuged and re-suspended in 300µL of PBS and fluorescence was measured using flow cytometry.[@CIT0034]

Fluorescence Imaging of 3D Spheroids {#S0002-S2013}
------------------------------------

The prepared 3D spheroids were treated with co-loaded LPHNPs to evaluate the qualitative uptake of LPHNPs by 3D spheroids. After 4 hrs of treatment, the spheroids were collected and fixed with 4% paraformaldehyde and kept at 4°C overnight. The spheroids were then treated with HOECHST 33342 and suitable images were taken using the fluorescence microscopy.

Results and Discussion {#S0003}
======================

Average Particle Size and Zeta Potential {#S0003-S2001}
----------------------------------------

The size and zeta potential of LPHNPs were determined by using the dynamic light scattering technique. The results indicated that the size of all the formulations with various ratios of lipid to chitosan was in the nanometer range and varies from 200 to 700nm. The surface charge of formulations remained positive till the 40:1 ratio of lipid to chitosan due to the cationic nature of chitosan and hybrid nanoparticles with lipid to chitosan ratio of 60:1 showed negative charge due to higher contents of lipids ([Table 1](#T0001){ref-type="table"}).[@CIT0035] The positive charge on the nanoparticles progressively decreases with an increase in lipid concentration. At lipid to chitosan ratio of 20:1, the hybrid nanoparticles were of suitable size with lower PDI and cationic surface charge.Table 1Size and Surface Charge of Cisplatin and Curcumin Dual Loaded LPHNPs. Results Indicate Mean ±SD, n=3Lipid:Polymer RatioSize (nm)PDIPotential (mV)5:1437.3±2.20.32±0.0245.5±1.810:1276.7±2.80.29±0.0345.2±1.320:1225.5±0.80.21±0.0132.6±0.730:1392.7±1.20.33±0.0430.3±1.240:1353.9±1.40.35±0.0521.6±1.160:1680.1±1.10.19±0.07−0.21±0.6

Entrapment Efficiency and Drug Loading {#S0003-S2002}
--------------------------------------

The entrapment efficiency of prepared LPHNPs was calculated by the indirect method. LPHNPs with different ratios of lipid to chitosan showed more than 75% encapsulation efficiency and nanoparticles with lipid to chitosan ratio of 20:1 showed more than 85% encapsulation efficiency ([Table 2](#T0002){ref-type="table"}). The encapsulation efficiency is higher than polymeric nanoparticles and is attributed to the presence of lipid layer. The formulations with a lower ratio of lipids showed lower encapsulation of curcumin, as the ratio of lipid is increased the encapsulation efficiency of curcumin is increased because of its better solubility in lipophilic phase and incorporation inside the hybrid system. The hybrid nanoparticles system serves as a reservoir and incorporate both lipophilic and hydrophilic drugs with high encapsulation efficiency and avoid irregular drug release.[@CIT0036] The hybrid nanoparticles with lipid to chitosan ratio of 20:1 were selected for further studies.Table 2Encapsulation Efficiency and Drug Loading of Cisplatin and Curcumin. Results Indicate Mean ±SD, n=3Lipid:Polymer RatioEE (%) CurcuminDL (%) CurcuminEE (%) CisplatinDL (%) Cisplatin5:160.3±2.21.1±0.479.5±2.31.5±0.410:167.7±2.81.2±0.381.2±1.81.4±0.320:178.5±0.82.1±0.285.6±0.92.3±0.230:175.7±1.21.4±0.382.1±1.51.8±0.340:177.9±1.42.1±0.576.5±1.11.7±0.560:181.1±1.12.5±0.675.1±1.41.5±0.6

Morphology {#S0003-S2003}
----------

The morphology of LPHNPs was evaluated using the transmission electron microscope (Jeol, USA). The images showed spherical-shaped nanoparticles ([Figure 2](#F0002){ref-type="fig"}). The size of LPHNPs was in the range of 225 nm, which is in accordance with the size determined by dynamic light scattering technique. The morphology of curcumin and cisplatin co-loaded nanoparticles was similar to previously reported with curcumin and doxorubicin co-loaded nanoparticles.[@CIT0037],[@CIT0038] The lipid and chitosan interact with each other via ionic gelation and form spherical-shaped nanoparticles.Figure 2Transmission electron microscopy images of curcumin and cisplatin co-loaded LPHNPs.

In vitro Drug Release Studies {#S0003-S2004}
-----------------------------

The release of both cisplatin and curcumin was observed using the dialysis bag method. Phosphate buffer saline pH 7.4 was used as a dissolution medium.[@CIT0039] There was not any burst release of cisplatin or curcumin from the LPHNPs. The results showed that both cisplatin and curcumin released in a controlled manner from lipid-chitosan hybrid nanoparticles while there is some burst release in the case of free cisplatin and curcumin. The results indicated that only 50% of curcumin is released from hybrid nanoparticles in 24 hrs and controlled release behavior of curcumin from nanoparticles was observed, which is also reported in previous chitosan nanoparticles loaded with curcumin.[@CIT0040] The release of cisplatin was also controlled and only 68% of cisplatin in released in 24 hrs ([Figure 3](#F0003){ref-type="fig"}). This is suitable for the sustained delivery of drugs and to avoid a higher therapeutic level. The lipid-chitosan hybrid nanoparticles are suitable for the controlled release of both lipophilic and hydrophilic drugs. The polymer provides higher encapsulation and avoids burst release of drug and lipid layer provides a diffusional barrier that further enhances the controlled release behavior of drug from hybrid nanoparticles.[@CIT0041]Figure 3Drug release profile of cisplatin and curcumin from LPHNPs.

Cell Viability Studies {#S0003-S2005}
----------------------

Cell viability studies were conducted to evaluate the therapeutic efficacy of curcumin and cisplatin co-loaded hybrid nanoparticles. The cytotoxicity was observed on A2780 cell lines after 24 and 48 hrs of treatment. The results indicated that after 24 hrs of treatment there is not much significant increase in cytotoxicity of co-loaded LPHNPs compared to cisplatin loaded LPHNPs but there is significant more cytotoxicity of co-loaded LPHNPs compared to curcumin loaded LPHNPs and curcumin solution. There insignificant difference in cytotoxicity after 24 hrs of treatment was because of the controlled release of cisplatin and curcumin from hybrid nanoparticles while free drugs have easy access to the cells.

After 48 hrs of treatment, cisplatin and curcumin co-loaded LPHNPs have more significant cytotoxicity compared to cisplatin loaded LPHNPs and curcumin loaded LPHNPs particularly at concentrations of 6.2 and 3.1µg/mL. This showed that the addition of curcumin to cisplatin nanoparticles increase the chemosensitization of ovarian cells and resulted in higher cytotoxic effects ([Figure 4](#F0004){ref-type="fig"}). The curcumin has cytotoxic effect toward cancer cells and the combination leads to synergistic effect and higher cytotoxicity toward ovarian cell lines.[@CIT0042] The synergistic anticancer effect of both cisplatin and curcumin also leads to enhanced therapeutic efficacy.[@CIT0043] The curcumin arrests the cell cycle at the G~2~/M phase of the cell cycle and cisplatin also inhibit the cells at the G~2~/M phase of the cell cycle. This peculiar combination of cisplatin and curcumin leads to synergistic cytotoxic effects.[@CIT0044]Figure 4Cytotoxicity studies of cisplatin and curcumin co-loaded LPHNPs on A2780 cell lines after 24 hrs and 48 hrs of treatment. All results indicate mean ± SD, n=3. \*P \< 0.05, \*\*P \< 0.01, \*\*\*P \< 0.001.

Cell Uptake Studies {#S0003-S2006}
-------------------

The cell uptake studies were conducted to determine the uptake of curcumin and cisplatin co-loaded LPHNPs by A2780 ovarian cell lines.

The uptake of LPHNPs by the cells was determined qualitatively by fluorescence microscopy. The results indicated that co-loaded LPHNPs loaded with fluorescence dye rhodamine-123 produced enhanced green fluorescence, which indicates the uptake of nanoparticles by the cells and hybrid nanoparticles loaded with Rh-PE produces red fluorescence which also confirmed the uptake of nanoparticles by the cells. The addition of curcumin in nanoparticles along with fluorescent dyes produces strong fluorescence ([Figure 5A](#F0005){ref-type="fig"}). The curcumin is also known to produce slight green fluorescence hence the cells showed more bright green fluorescence in combination of curcumin and rhodamine-123. The inherent slight green fluorescence of curcumin is also reported in other studies.[@CIT0045]Figure 5(**A**) Fluorescence microscopy images of curcumin and cisplatin co-loaded LPHNPs (**B**) cell uptake of curcumin and cisplatin loaded LPHNPs. All results indicate mean ± SD, n=3. \*P \< 0.05.

To quantitatively determine the uptake of cisplatin loaded LPHNPs and co-loaded LPHNPs and to differentiate the effect of added curcumin on the uptake of nanoparticles, we performed the FACS analysis. The results indicated that there is a 10-fold uptake of cisplatin loaded LPHNPs and 12-fold uptake of curcumin and cisplatin co-loaded LPHNPs by the cells compared to control ([Figure 5B](#F0005){ref-type="fig"}). There is a significant increase in uptake as of co-loaded LPHNPs compared to control and cisplatin loaded LPHNPs. These results showed that the addition of curcumin to LPHNPs enhanced their uptake by the cells that lead to higher internalization and increased cytotoxic effect. Previous studies on curcumin nanoparticles also showed enhanced uptake of curcumin loaded nanoparticles by the cells.[@CIT0046] The inherent green fluorescence is also detectable quantitatively by FACS analysis and co-loaded LPHNPs showed more uptake than cisplatin loaded LPHNPs with an equal amount (0.5 mole percent) of rhodamine-123 incorporated inside both LPHNPs.[@CIT0047]

Cytotoxicity Toward 3D Spheroids {#S0003-S2007}
--------------------------------

The cytotoxicity studies were conducted on 3D spheroids as a tumor model to evaluate the therapeutic efficacy of co-loaded LPHNPs. The cytotoxicity was observed after one and two days of treatment. The results indicated that blank nanoparticles do not have any cytotoxic effects and are biocompatible. Previous studies showed that 3D spheroids are known to mimic the in-vivo tumor environment and serve as a tool to evaluate the therapeutic efficacy of nanoparticles in the in-vivo environment.[@CIT0048]

The results indicated that after 24 hrs of treatment co-loaded LPHNPs have more cytotoxic effect compared to cisplatin solution at concentrations of 12.5, 6.2 and 3.1 µg/mL and is more significant at 12.5µg/mL. Similarly, co-loaded LPHNPs have more cytotoxic effect compared to cisplatin loaded LPHNPs at concentrations of 12.5 and 6.2 µg/mL. The co-loaded LPHNPs showed enhanced cytotoxicity even after 24 hrs of incubation compared to monolayer cells because cisplatin solution cannot easily penetrate inside 3D spheroids while co-loaded LPHNPs have been actively taken up by 3D spheroids.

After 48 hrs of treatment co-loaded LPHNPs produce significant cytotoxic effect compared to cisplatin solution and cisplatin loaded LPHNPs on 3D spheroids. These results indicated that the therapeutic effect of cisplatin in increased by the addition of curcumin, which is known to reduce the resistance of cisplatin ([Figure 6](#F0006){ref-type="fig"}). The higher cytotoxicity is observed after 48 hrs of treatment due to the controlled release of curcumin and cisplatin from the hybrid nanoparticle. Previous studies on 3D spheroids also showed the enhanced cytotoxic effect of co-loaded curcumin nanoparticles.[@CIT0049]Figure 6Cytotoxicity studies on 3D spheroids of curcumin and cisplatin co-loaded LPHNPs and cisplatin loaded LPHNPs and cisplatin solution. All results indicate mean ± SD, n=3. \*P \< 0.05, \*\*P \< 0.01, \*\*\*P \< 0.001.

Cell Uptake Studies of 3D Spheroids {#S0003-S2008}
-----------------------------------

The uptake of curcumin and cisplatin loaded LPHNPs by 3D spheroids was evaluated qualitatively using fluorescence microscopy. The fluorescent dye rhodamine-PE was incorporated into the co-loaded LPHNPs and fluorescence microscopy images of spheroids showed that there is significant uptake of co-loaded LPHNPs compared to control ([Figure 7A](#F0007){ref-type="fig"}).Figure 7(**A**) Fluorescence microscopy images of curcumin+ cisplatin co-loaded LPHNPs (**B**) Cell uptake studies of curcumin + cisplatin co-loaded LPHNPs. All results indicate mean ± SD, n=3. \*\*P \< 0.01.

To quantitatively determine the uptake of co-loaded LPHNPs and to compare with cisplatin loaded LPHNPs we performed FACS analysis. The results indicated that there is a 4-fold increase in uptake of cisplatin loaded LPHNPs and there is a 5-fold increase in uptake of co-loaded LPHNPs compared to control ([Figure 7B](#F0007){ref-type="fig"}). The results indicated that there was a slight increase in uptake by the addition of curcumin.

The co-loaded LPHNPs have successfully crossed that upper layer of 3D spheroids and penetrated into the deeper layer and produce fluorescence.[@CIT0050] The co-loaded LPHNPs showed enhanced cellular internalization due to non-specific interaction with the cell membrane and lead to enhanced fluorescence.[@CIT0051]

Conclusion {#S0004}
==========

Lipid-chitosan hybrid nanoparticles were successfully fabricated for co-delivery of cisplatin and curcumin. The nanoparticles with different ratios of lipid and chitosan were prepared with suitable size and enhanced encapsulation efficiency. The encapsulation of curcumin increased with an increase in lipid concentration. The drug release from the LPHNPs was in a controlled manner and the absence of burst release indicated proper encapsulation of both curcumin and cisplatin. The combination of lipid and polymer served as an excellent vehicle for the controlled release of drugs. Polymer provides structural integrity and lipid layer prevents leakage of drug from the LPHNPs. The in vitro cytotoxicity studies revealed enhanced therapeutic efficacy of co-loaded LPHNPs compared to cisplatin loaded LPHNPs and curcumin loaded LPHNPs. The cell uptake studies revealed enhanced uptake of co-loaded LPHNPS. The therapeutic efficacy of co-loaded LPHNPs was further evaluated on 3D spheroids as an in-vivo tumor model. It was concluded that co-loaded LPHNPs showed enhanced cytotoxicity and the addition of curcumin to cisplatin leads to increased chemosensitization of 3D spheroids toward cisplatin.

The authors acknowledge the International Research Support Initiative Program (IRSIP) of the Higher Education Commission of Pakistan for the travel grant to Northeastern University, Boston, USA. The authors also acknowledge support by center of Pharmaceutical Biotechnology and Nanomedicines, Northeastern University, Boston, MA, USA.

Disclosure {#S0005}
==========

The authors report no conflicts of interest in this work.
